LITHIUM CARBONATE INHIBITION OF I-131 RELEASE BY THYR.CARCINOMA

碳酸锂抑制甲状腺癌释放 I-131

• 批准号: 3896262
• 负责人: J ROBBINS
• 金额: --
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3896262
• 关键词: carbonates; cell differentiation; hormone inhibitor; human subject; human therapy evaluation; lithium; magnetic resonance imaging; neoplasm /cancer radionuclide therapy; nuclear medicine; radiation dosage; radionuclide imaging /scanning; radiotracer; thyroid neoplasm

The Clinical Endocrinology Branch has a follow-up study of the treatment of differentiated thyroid Carcinoma. In this study patients are often given I-131 treatment. Lithium carbonate inhibits the release of thyroid hormone by the normal thyroid gland. In the thyroid carcinoma project, lithium carbonate is given to patients with differentiated thyroid carcinoma to block the release of I-131 from tumor deposits. Successful blockade of the I-131 release prolongs the residence time of the I-131 in the tumor and thus increases the radiation dose delivered per mC trapped by the tumor. In the study patients are given two 1.5 mCi tracer doses of I-131. Serial Nuclear Medicine images of the activity in the tumor are obtained after the doses and the biological T1/2 of I-131 residence in the tumor is calculated. The initial study, a baseline evaluation, is followed by a second study performed when the patient is taking Lithium. The purpose of the study is to determine the frequency of a lithium effect, and to determine whether a significant increase in the radiation dose delivered to the tumor can be achieved. A preliminary report of this study has been published.

临床内分泌学分支有一项关于治疗 分化型甲状腺癌 在这项研究中， I-131治疗 碳酸锂抑制甲状腺激素的释放 正常的甲状腺。 在甲状腺癌项目中，锂 碳酸盐用于分化型甲状腺癌患者， 阻断肿瘤沉积物中I-131的释放。 成功封锁了 I-131的释放缩短了I-131在肿瘤中的停留时间， 因此增加了由肿瘤捕获的每mC递送的辐射剂量。 在研究中，患者接受了两次1.5 mCi示踪剂剂量的I-131。 串行 肿瘤中活性的核医学图像是在放射治疗后获得的。 剂量和I-131在肿瘤中驻留的生物T1/2是 计算了 最初的研究是一项基线评估，随后是一项 当患者服用锂时进行的第二项研究。 的目的 这项研究是为了确定锂效应的频率， 确定输送至患者的辐射剂量是否显著增加 肿瘤可以实现。 这项研究的初步报告已经 公开.